 Eric Rush
Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypophosphatasia | 10 | 2023 | 10 | 4.320 |
Why?
| | Osteogenesis Imperfecta | 7 | 2023 | 8 | 2.060 |
Why?
| | Alkaline Phosphatase | 9 | 2023 | 18 | 1.910 |
Why?
| | Bone Density Conservation Agents | 5 | 2023 | 10 | 1.470 |
Why?
| | Humans | 44 | 2023 | 6599 | 1.470 |
Why?
| | Recombinant Fusion Proteins | 5 | 2021 | 12 | 1.330 |
Why?
| | Craniofacial Abnormalities | 4 | 2020 | 10 | 1.330 |
Why?
| | Immunoglobulin G | 5 | 2021 | 33 | 1.330 |
Why?
| | Bone Density | 5 | 2023 | 43 | 1.310 |
Why?
| | Male | 28 | 2023 | 3197 | 1.280 |
Why?
| | Female | 22 | 2023 | 3436 | 1.240 |
Why?
| | Genetic Diseases, X-Linked | 2 | 2021 | 4 | 1.210 |
Why?
| | Intellectual Disability | 5 | 2023 | 31 | 1.190 |
Why?
| | Diphosphonates | 4 | 2023 | 13 | 1.150 |
Why?
| | Developmental Disabilities | 6 | 2023 | 38 | 1.110 |
Why?
| | Adolescent | 15 | 2023 | 2087 | 1.060 |
Why?
| | Child | 20 | 2023 | 3146 | 0.980 |
Why?
| | Mutation | 11 | 2023 | 194 | 0.980 |
Why?
| | Osteoporosis | 3 | 2019 | 25 | 0.910 |
Why?
| | Infant | 15 | 2023 | 1396 | 0.900 |
Why?
| | Child, Preschool | 14 | 2023 | 1459 | 0.860 |
Why?
| | Phenotype | 13 | 2023 | 233 | 0.850 |
Why?
| | Hypophosphatemia | 1 | 2021 | 5 | 0.840 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2021 | 9 | 0.830 |
Why?
| | Neurodevelopmental Disorders | 4 | 2023 | 19 | 0.810 |
Why?
| | Zellweger Syndrome | 3 | 2015 | 3 | 0.800 |
Why?
| | Abnormalities, Multiple | 2 | 2013 | 36 | 0.800 |
Why?
| | Adult | 13 | 2023 | 1233 | 0.720 |
Why?
| | Cost of Illness | 1 | 2019 | 19 | 0.710 |
Why?
| | Congenital Disorders of Glycosylation | 1 | 2017 | 1 | 0.630 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2017 | 2 | 0.630 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 9 | 0.620 |
Why?
| | Aorta | 1 | 2016 | 8 | 0.590 |
Why?
| | Bone Diseases, Metabolic | 2 | 2017 | 8 | 0.580 |
Why?
| | Hearing Loss | 2 | 2013 | 4 | 0.560 |
Why?
| | Heart Ventricles | 1 | 2016 | 50 | 0.560 |
Why?
| | PPAR gamma | 1 | 2015 | 1 | 0.560 |
Why?
| | Echocardiography | 1 | 2016 | 78 | 0.560 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 49 | 0.560 |
Why?
| | Anemia, Aplastic | 1 | 2015 | 1 | 0.560 |
Why?
| | Sex Chromosome Disorders of Sex Development | 1 | 2015 | 1 | 0.560 |
Why?
| | Trisomy | 1 | 2015 | 2 | 0.560 |
Why?
| | Opportunistic Infections | 1 | 2015 | 7 | 0.550 |
Why?
| | Chromosome Deletion | 2 | 2016 | 14 | 0.500 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2013 | 1 | 0.470 |
Why?
| | Cleft Lip | 1 | 2013 | 5 | 0.470 |
Why?
| | Cleft Palate | 1 | 2013 | 8 | 0.470 |
Why?
| | Neurocutaneous Syndromes | 1 | 2013 | 1 | 0.460 |
Why?
| | Alopecia | 1 | 2013 | 2 | 0.460 |
Why?
| | Membrane Proteins | 4 | 2019 | 50 | 0.450 |
Why?
| | Treatment Outcome | 4 | 2021 | 624 | 0.450 |
Why?
| | Growth Disorders | 1 | 2013 | 24 | 0.450 |
Why?
| | Fractures, Bone | 3 | 2023 | 35 | 0.440 |
Why?
| | Home Care Services | 1 | 2012 | 7 | 0.420 |
Why?
| | Health Care Surveys | 1 | 2012 | 32 | 0.420 |
Why?
| | Growth | 1 | 2011 | 9 | 0.410 |
Why?
| | Genomics | 2 | 2023 | 86 | 0.410 |
Why?
| | Body Composition | 1 | 2011 | 26 | 0.410 |
Why?
| | Ambulatory Care | 1 | 2012 | 46 | 0.410 |
Why?
| | Adipose Tissue | 1 | 2011 | 27 | 0.400 |
Why?
| | Young Adult | 5 | 2023 | 652 | 0.400 |
Why?
| | Prevalence | 3 | 2023 | 145 | 0.390 |
Why?
| | Body Mass Index | 1 | 2011 | 155 | 0.380 |
Why?
| | Infant, Newborn | 5 | 2023 | 790 | 0.380 |
Why?
| | Comparative Genomic Hybridization | 1 | 2010 | 7 | 0.370 |
Why?
| | Sequence Deletion | 1 | 2010 | 8 | 0.370 |
Why?
| | Obesity | 1 | 2011 | 124 | 0.370 |
Why?
| | Bone Diseases | 2 | 2019 | 4 | 0.350 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 317 | 0.350 |
Why?
| | Europe | 2 | 2023 | 33 | 0.340 |
Why?
| | Haploinsufficiency | 3 | 2021 | 8 | 0.280 |
Why?
| | Karyotyping | 2 | 2015 | 8 | 0.260 |
Why?
| | Retrospective Studies | 5 | 2023 | 1251 | 0.250 |
Why?
| | Autistic Disorder | 2 | 2021 | 12 | 0.250 |
Why?
| | PHEX Phosphate Regulating Neutral Endopeptidase | 2 | 2021 | 2 | 0.250 |
Why?
| | Rare Diseases | 2 | 2022 | 37 | 0.250 |
Why?
| | Genetic Testing | 2 | 2021 | 74 | 0.230 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 5 | 0.220 |
Why?
| | Insurance Coverage | 1 | 2023 | 19 | 0.220 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2022 | 20 | 0.220 |
Why?
| | Hermanski-Pudlak Syndrome | 1 | 2021 | 1 | 0.210 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 27 | 0.210 |
Why?
| | Enzyme Replacement Therapy | 2 | 2018 | 4 | 0.210 |
Why?
| | Calcium Channels, L-Type | 1 | 2021 | 5 | 0.210 |
Why?
| | Long QT Syndrome | 1 | 2021 | 3 | 0.210 |
Why?
| | Syndactyly | 1 | 2021 | 4 | 0.200 |
Why?
| | Quality of Life | 2 | 2019 | 131 | 0.200 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 4 | 0.200 |
Why?
| | Genes, Recessive | 1 | 2021 | 6 | 0.200 |
Why?
| | Spliceosomes | 1 | 2021 | 1 | 0.200 |
Why?
| | Mandibulofacial Dysostosis | 1 | 2021 | 2 | 0.200 |
Why?
| | Ellis-Van Creveld Syndrome | 1 | 2020 | 1 | 0.200 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2020 | 1 | 0.200 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 5 | 0.200 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 62 | 0.190 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2020 | 2 | 0.190 |
Why?
| | DNA Helicases | 1 | 2020 | 5 | 0.190 |
Why?
| | Brain | 2 | 2012 | 74 | 0.190 |
Why?
| | Myotonin-Protein Kinase | 1 | 2020 | 1 | 0.190 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 16 | 0.190 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 96 | 0.180 |
Why?
| | Muscle Weakness | 1 | 2019 | 2 | 0.180 |
Why?
| | Telephone | 1 | 2019 | 12 | 0.180 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 9 | 0.180 |
Why?
| | Severity of Illness Index | 2 | 2018 | 142 | 0.180 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 215 | 0.180 |
Why?
| | Mobility Limitation | 1 | 2019 | 3 | 0.180 |
Why?
| | Case-Control Studies | 2 | 2016 | 202 | 0.170 |
Why?
| | Peroxisomes | 2 | 2015 | 2 | 0.170 |
Why?
| | Pain | 1 | 2019 | 53 | 0.170 |
Why?
| | Fracture Fixation, Intramedullary | 1 | 2018 | 1 | 0.170 |
Why?
| | Osteotomy | 1 | 2018 | 1 | 0.170 |
Why?
| | Tibia | 1 | 2018 | 1 | 0.170 |
Why?
| | Femur | 1 | 2018 | 10 | 0.170 |
Why?
| | Testosterone | 1 | 2018 | 11 | 0.160 |
Why?
| | Syndrome | 2 | 2020 | 33 | 0.160 |
Why?
| | Lung | 1 | 2018 | 65 | 0.160 |
Why?
| | Osteopetrosis | 1 | 2017 | 1 | 0.160 |
Why?
| | Ichthyosis | 1 | 2017 | 2 | 0.160 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 290 | 0.160 |
Why?
| | Lipid Metabolism | 1 | 2017 | 6 | 0.160 |
Why?
| | Siblings | 1 | 2017 | 7 | 0.160 |
Why?
| | Outpatients | 1 | 2017 | 28 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2017 | 19 | 0.150 |
Why?
| | Inpatients | 1 | 2017 | 44 | 0.150 |
Why?
| | Nebraska | 1 | 2016 | 2 | 0.150 |
Why?
| | Ventricular Remodeling | 1 | 2016 | 3 | 0.150 |
Why?
| | Dilatation, Pathologic | 1 | 2016 | 6 | 0.150 |
Why?
| | Observer Variation | 1 | 2016 | 12 | 0.150 |
Why?
| | Vascular Remodeling | 1 | 2016 | 2 | 0.150 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2016 | 6 | 0.150 |
Why?
| | Tourette Syndrome | 1 | 2016 | 6 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 50 | 0.150 |
Why?
| | Chromosome Disorders | 1 | 2016 | 6 | 0.150 |
Why?
| | Receptor, Parathyroid Hormone, Type 1 | 1 | 2016 | 2 | 0.150 |
Why?
| | Osteochondrodysplasias | 1 | 2016 | 3 | 0.150 |
Why?
| | Ventricular Function, Left | 1 | 2016 | 25 | 0.150 |
Why?
| | Hypercalcemia | 1 | 2016 | 10 | 0.150 |
Why?
| | Parathyroid Hormone | 1 | 2016 | 24 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 99 | 0.140 |
Why?
| | Peroxisomal Disorders | 1 | 2015 | 1 | 0.140 |
Why?
| | Lumbosacral Region | 1 | 2015 | 1 | 0.140 |
Why?
| | Femur Neck | 1 | 2015 | 6 | 0.140 |
Why?
| | Sex Chromosome Aberrations | 1 | 2015 | 1 | 0.140 |
Why?
| | Osteogenesis | 1 | 2015 | 6 | 0.140 |
Why?
| | Chromosomes, Human, X | 1 | 2015 | 5 | 0.140 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 17 | 0.140 |
Why?
| | Tracheoesophageal Fistula | 1 | 2016 | 26 | 0.140 |
Why?
| | Reproducibility of Results | 1 | 2016 | 197 | 0.140 |
Why?
| | Graft Survival | 1 | 2015 | 31 | 0.140 |
Why?
| | Vitamin D | 1 | 2015 | 21 | 0.140 |
Why?
| | Cohort Studies | 2 | 2019 | 264 | 0.140 |
Why?
| | Pedigree | 3 | 2022 | 53 | 0.130 |
Why?
| | Prospective Studies | 1 | 2016 | 508 | 0.130 |
Why?
| | Middle Aged | 3 | 2023 | 648 | 0.120 |
Why?
| | Factor VII Deficiency | 1 | 2014 | 2 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 4 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2014 | 43 | 0.110 |
Why?
| | Corneal Diseases | 1 | 2013 | 1 | 0.110 |
Why?
| | Hypesthesia | 1 | 2013 | 1 | 0.110 |
Why?
| | Rhombencephalon | 1 | 2013 | 1 | 0.110 |
Why?
| | Cerebellum | 1 | 2013 | 13 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 2 | 2012 | 114 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 26 | 0.110 |
Why?
| | Patient Satisfaction | 1 | 2012 | 41 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 36 | 0.100 |
Why?
| | Program Evaluation | 1 | 2012 | 52 | 0.100 |
Why?
| | New Zealand | 1 | 2011 | 4 | 0.100 |
Why?
| | Frameshift Mutation | 2 | 2022 | 5 | 0.100 |
Why?
| | Anthropometry | 1 | 2011 | 16 | 0.100 |
Why?
| | Genotype | 2 | 2023 | 395 | 0.100 |
Why?
| | Overweight | 1 | 2011 | 48 | 0.100 |
Why?
| | Age Factors | 1 | 2011 | 203 | 0.100 |
Why?
| | Glucose Transporter Type 4 | 1 | 2010 | 1 | 0.090 |
Why?
| | Connexins | 1 | 2010 | 3 | 0.090 |
Why?
| | Aged | 2 | 2019 | 375 | 0.080 |
Why?
| | Prognosis | 2 | 2019 | 209 | 0.080 |
Why?
| | Delayed Diagnosis | 1 | 2023 | 3 | 0.060 |
Why?
| | Artificial Intelligence | 1 | 2023 | 9 | 0.060 |
Why?
| | Fracture Fixation | 1 | 2023 | 1 | 0.060 |
Why?
| | Teriparatide | 1 | 2023 | 1 | 0.060 |
Why?
| | Vomiting | 1 | 2023 | 23 | 0.060 |
Why?
| | Muscle Hypotonia | 1 | 2022 | 6 | 0.060 |
Why?
| | Genome | 1 | 2022 | 30 | 0.050 |
Why?
| | Sequence Analysis, DNA | 1 | 2022 | 106 | 0.050 |
Why?
| | Craniofacial Dysostosis | 1 | 2021 | 1 | 0.050 |
Why?
| | Limb Deformities, Congenital | 1 | 2021 | 2 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 94 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 3 | 0.050 |
Why?
| | Catalytic Domain | 1 | 2020 | 4 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2020 | 27 | 0.050 |
Why?
| | Heterozygote | 1 | 2020 | 23 | 0.050 |
Why?
| | Mutation, Missense | 1 | 2020 | 24 | 0.050 |
Why?
| | Ligands | 1 | 2019 | 5 | 0.040 |
Why?
| | North America | 1 | 2019 | 42 | 0.040 |
Why?
| | Vital Capacity | 1 | 2018 | 6 | 0.040 |
Why?
| | Spirometry | 1 | 2018 | 6 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2018 | 10 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2018 | 16 | 0.040 |
Why?
| | Internal Fixators | 1 | 2018 | 3 | 0.040 |
Why?
| | Radioimmunoassay | 1 | 2018 | 3 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2018 | 8 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2018 | 16 | 0.040 |
Why?
| | Reoperation | 1 | 2018 | 57 | 0.040 |
Why?
| | Calcitriol | 1 | 2017 | 6 | 0.040 |
Why?
| | Animals | 1 | 2019 | 563 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 51 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 43 | 0.040 |
Why?
| | Consensus | 1 | 2017 | 31 | 0.040 |
Why?
| | Incidence | 1 | 2017 | 125 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 116 | 0.040 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 2016 | 2 | 0.040 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2016 | 2 | 0.040 |
Why?
| | Retinal Dystrophies | 1 | 2015 | 1 | 0.040 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2015 | 3 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2016 | 33 | 0.030 |
Why?
| | Precision Medicine | 1 | 2015 | 42 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2016 | 315 | 0.030 |
Why?
| | Risk Factors | 1 | 2016 | 460 | 0.030 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 7 | 0.030 |
Why?
| | Indians, North American | 1 | 2012 | 9 | 0.030 |
Why?
| | Exons | 1 | 2012 | 32 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|